Navigation Links
Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
Date:9/30/2010

ible," said Steve Harris, Circassia's CEO. "Since the founding of Circassia just four years ago, our ToleroMune(R) technology has successfully completed multiple phase II studies, and we now have four therapies in mid-stage development, targeting some of the most common allergies in the world. As a result, our growing clinical database demonstrates the potential of our novel T-cell vaccines to provide allergy sufferers with short, simple and convenient treatment, whilst minimising the risk of severe and sometimes life-threatening side effects associated with many existing immunotherapies."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's allergy T-cell vaccines show that short treatment regimes can greatly reduce patients' allergic reactions, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy treatments offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potential regulatory and supply chain benefits. The short peptides utilised in Circassia's vaccines are manufactured chemically, in contrast to existing allergen immunotherapies, which are purified from natural sources. Circassia's approach applies the chemistry, manufacturing and control standards associated with conventional pharmaceuticals to its allergy T-cell vaccines. This fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceu
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
2. Circassia Acquires North American and Japanese Rights to Dopexamine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LAUSANNE, Switzerland, September 3 Debiopharm Group, ... with,a focus on the development of prescription drugs ... Life Sciences Award, to Dr Lluis,Quintana-Murci from the ... in the emerging field of evolutionary genetics of,infection. ...
... JERUSALEM, September 3 Oramed Pharmaceuticals,Inc. (OTC ... systems, announced today that Nadav Kidron, its Chief Executive,Officer, is ... Conference on Friday September 11, 2009 at 10:00 a.m. EDT. ... in New York City. , Nadav ...
... , , BEIJING, Sept. 3 ... President Chung Leik Kok, announced today the signing of two (2) ... and Chemical Co., Ltd. (Beijing Oil & Gas). Fauve Intertrade is ... Miami, Florida; and Kuala Lumpur, Malaysia - with offices opening in ...
Cached Biology Technology:The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 2The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 3Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference 2Fauve Intertrade Signs Major Energy Contracts in China 2
(Date:4/23/2014)... a newly coined term for novels and films which focus ... of Copenhagen shows how these fictions serve as a mental ... climate change and imagine other living conditions. , "Global ... the atmosphere; it is also a cultural phenomenon in which ... the films we see. And there are so many of ...
(Date:4/23/2014)... University of Exeter researcher has shed light on how ... in Australia,s remote outback have become reviled as pests ... of the Environment and Sustainability Institute at the University ... camel in Australia, from their historic role helping to ... as unwelcome "invader." , The deserts of the Australian ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3
... States, (U.S.) predominance in science and technology (S&T) eroded ... China and South Korea--rapidly increased their innovation capacities. According ... Board (NSB), the policy making body of the National ... and Congress, the major Asian economies, taken together, now ...
... , This news release is available in ... transmission at the synapse between neurons is a highly complex, but ... voltage change, the so-called action potential, reaches the synaptic terminal in ... presynaptic neuron. This influx leads to a rise in the intracellular ...
... led by scientists from the University of California, San ... a protein that broadly regulates how genetic information transcribed ... ultimately translated into the myriad of proteins necessary for ... Cell Reports , help explain how a relatively ...
Cached Biology News:US lead in science and technology shrinking 2US lead in science and technology shrinking 3US lead in science and technology shrinking 4Loose coupling between calcium channels and sensors 2Global regulator of mRNA editing found 2
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Biology Products: